Irbesartan

證據等級: L5

預測適應症: 4 個

Irbesartan: From Hypertension to Malignant Renovascular Hypertension

One-Sentence Summary

Irbesartan (DrugBank DB01029) is an angiotensin II receptor blocker (ARB) whose established indication is hypertension (this evidence pack does not carry a confirmed Taiwan/US regulatory filing for it — see Data Gaps below). The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, but currently no clinical trials and no literature directly support this specific indication — the prediction rests on mechanistic plausibility (RAAS inhibition) alone.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack’s Taiwan regulatory data (drug shows as unmarketed, 0 licenses); per general ARB-class pharmacology: hypertension
Predicted New Indication	Malignant Renovascular Hypertension
TxGNN Prediction Score	99.31%
Evidence Level	L5 (model prediction only, no clinical trial or literature support)
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Note: two closely related predictions score nearly identically — “malignant hypertensive renal disease” (rank 2, score 99.31%) is mechanistically the same pathology (renal sequela of malignant hypertension) and carries the same evidence gap. “Pulmonary hypertension owing to lung disease/hypoxia” (rank 3) and “pulmonary hypertension with unclear multifactorial mechanism” (rank 4) score similarly (~99.25%) but ARB is not a standard mechanistic fit for WHO Group 3/5 pulmonary hypertension, and the 20 PubMed hits returned for rank 3 are generic hypoxia/oncology biology papers unrelated to irbesartan or pulmonary hypertension treatment — they do not constitute supporting evidence.

Why is This Prediction Reasonable?

Detailed, source-verified mechanism-of-action data is not available in this evidence pack (original_moa is flagged as a High-severity data gap). Based on general pharmacological classification, irbesartan is an angiotensin II receptor blocker (ARB) that inhibits the renin-angiotensin-aldosterone system (RAAS), and its efficacy in essential hypertension is well established as a drug class.

Malignant renovascular hypertension arises from renal artery stenosis driving pathological RAAS overactivation, which produces both severe hypertension and progressive renal injury. Mechanistically, ARB-mediated RAAS blockade is a direct pharmacological counter to this pathway, which is consistent with the very high TxGNN score (0.993) for both this indication and its closely related renal-disease counterpart.

However, this mechanistic plausibility has not been corroborated by any indication-specific clinical trial or publication in this evidence pack — the searches returned zero results for both malignant renovascular hypertension and malignant hypertensive renal disease across ClinicalTrials.gov, ICTRP, and PubMed. The prediction should therefore be read as a model-driven hypothesis grounded in class pharmacology, not as an evidence-backed repurposing candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

(TFDA warnings and contraindications are flagged as a Blocking data gap — S1 safety screening cannot proceed until this is obtained.)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high, and the RAAS-inhibition mechanism is biologically plausible for malignant renovascular hypertension, but there is zero clinical trial or literature evidence directly supporting this indication, and the drug’s Taiwan/US market status, MOA, and safety data (warnings/contraindications) are all unconfirmed or missing from this evidence pack.

To proceed, the following is needed:

TFDA package insert (warnings and contraindications) — currently a Blocking gap preventing safety screening
Confirmed original MOA and approved indication data from DrugBank/regulatory source — currently a High-severity gap
Indication-specific literature/trial search for irbesartan in renovascular or malignant hypertension (current pulmonary-hypertension literature hits are not relevant and should not be cited as support)
Confirmation of actual Taiwan/US marketing and license status, since this evidence pack currently shows the drug as unmarketed with zero licenses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.